Aptevo Therapeutics Reports $6.5 Million Q3 Loss and $8.3 Million in Cash

Aptevo Therapeutics reported a Q3 2026 net loss of $6.5M and $8.3M in cash. Clinical progress for mipletamig showed 79% remission in high-risk AML patients. August financing raised $4.5M gross. Phase 1b RAINIER trial nears completion, with regulatory interaction planned for 2027.

Original reporting
Published Nov 16, 2026, 1:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aptevo Therapeutics Reports $6.5 Million Q3 Loss and $8.3 Million in Cash — source image
Decision brief

The 30-second read

$APVONeutralMed
01

Why it matters

The disclosed Q3 loss and cash position raise short‑term financing risk, but the 79% remission rate in TP53‑mutated AML patients provides a compelling data point that may attract investors seeking early‑stage oncology breakthroughs.

02

Market read

First‑time disclosure of earnings and trial data for a micro‑cap biotech; relevant for traders monitoring biotech earnings and early‑stage trial outcomes.

03

What to watch

Potential upcoming financing round or partnership could mitigate cash concerns.

Relevance 8/10Novelty 8/10Timing: today

Background

Aptevo Therapeutics (NASDAQ:APVO) is a clinical‑stage biotech focused on trispecific antibodies for oncology.

Company-level read

Ticker impact

$APVONeutralHigh confidence
Context

Aptevo Therapeutics filed an 8‑K reporting Q3 2026 net loss of $6.5 M, cash of $8.3 M and positive Phase 1b data for mipletamig in TP53‑mutated AML.

Expected impact

likely downward pressure as the market prices the loss and cash shortage, tempered by potential upside from the trial results

Evidence & confidence

Micro‑cap biotech stocks react sharply to earnings misses and cash constraints, but positive early‑stage data can limit sell‑offs and attract speculative buying.

Market effects

Highlights ongoing interest in TP53‑mutated AML therapies, may spur peer biotech attention.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche oncology investors.

Counterpoint

Despite cash constraints, the high remission rate could justify a short‑term rally on speculative buying.

Key entities

  • Aptevo Therapeutics

    Clinical‑stage biotech developing mipletamig for AML.

Related articles

$APVOHighAI 8/10

Aptevo reports Q3 results, mipletamig AML trial data

Aptevo Therapeutics (APVO) reported a Q3 2026 net loss of $6.5M, down from $7.5M in Q3 2025. Cash reserves fell to $8.3M. The company shared positive clinical data for mipletamig in AML treatment, with 79% remission rate in a small trial. It aims to complete Phase 1b trials by year-end and plans regulatory interaction in early 2027. Aptevo raised $4.5M in August via warrant inducement and private placement.

$APVOHighAI 8/10

Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary

Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.

$APVOMedAI 8/10

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibits 99.1 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Ten of 47 patients re

$APVOMedAI 8/10

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-